Market Research Logo

Inborn Gene or Chromosome Alterations - Medical Devices Pipeline Assessment, 2016

Inborn Gene or Chromosome Alterations - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, “Inborn Gene or Chromosome Alterations - Medical Devices Pipeline Assessment, 2016 provides an overview of Inborn Gene or Chromosome Alterations currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Inborn Gene or Chromosome Alterations pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Inborn Gene or Chromosome Alterations under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Inborn Gene or Chromosome Alterations and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Inborn Gene or Chromosome Alterations under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Inborn Gene or Chromosome Alterations Overview
3 Products under Development
3.1 Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
3.2 Inborn Gene or Chromosome Alterations - Pipeline Products by Territory
3.3 Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
3.4 Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date
3.5 Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials
4 Inborn Gene or Chromosome Alterations - Pipeline Products under Development by Companies
4.1 Inborn Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development
4.2 Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
5 Inborn Gene or Chromosome Alterations Companies and Product Overview
5.1 3D Signatures Inc Company Overview
5.2 Agena Bioscience, Inc Company Overview
5.3 Amarantus Bioscience Holdings Inc Company Overview
5.4 Ariosa Diagnostics Inc Company Overview
5.5 Atomic International Company Overview
5.6 AutoGenomics Inc Company Overview
5.7 Avellino Lab USA, Inc. Company Overview
5.8 Baylor College of Medicine Company Overview
5.9 BCML GmbH Company Overview
5.10 BioCeps (Inactive) Company Overview
5.11 Celula Inc Company Overview
5.12 Children's Hospital Boston Company Overview
5.13 Cincinnati Children's Hospital Medical Center Company Overview
5.14 Columbia University Company Overview
5.15 Da An Gene Co Ltd Company Overview
5.16 Deutsches Institut fur Ernahrungsforschung Company Overview
5.17 Epinex Diagnostics, Inc. Company Overview
5.18 Fina Biotech Company Overview
5.19 Firalis SAS Company Overview
5.20 Fluidigm Corp Company Overview
5.21 Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung eV Company Overview
5.22 Genekam Biotechnology AG Company Overview
5.23 Genentech Inc Company Overview
5.24 Genetic Analysis AS Company Overview
5.25 GENEWIZ Inc Company Overview
5.26 German Cancer Research Center Company Overview
5.27 GILUPI Nanomedizin Company Overview
5.28 Good Start Genetics Inc Company Overview
5.29 Goodgene Inc Company Overview
5.30 Hadassah Medical Center Company Overview
5.31 Helicos BioSciences Corporation Company Overview
5.32 Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH) Company Overview
5.33 Illumina, Inc. Company Overview
5.34 Immunexpress Pty Ltd Company Overview
5.35 Inform Genomics Inc Company Overview
5.36 Institute of Cancer Research Company Overview
5.37 Interleukin Genetics Inc Company Overview
5.38 John Hopkins University Company Overview
5.39 JS Genetics Inc Company Overview
5.40 Juneau Biosciences LLC Company Overview
5.41 KellBenx Inc Company Overview
5.42 Laboratory Corp of America Holdings Company Overview
5.43 Laval University Company Overview
5.44 Maastricht University Medical Center Company Overview
5.45 Massachusetts Eye and Ear Infirmary Company Overview
5.46 Max-Delbruck-Centrum fur Molekulare Medizin (MDC) Company Overview
5.47 Medical Research Council Company Overview
5.48 National Institute of Immunohaematology Company Overview
5.49 National University of Singapore Company Overview
5.50 NewGene Ltd Company Overview
5.51 Northwestern University Company Overview
5.52 NX PharmaGen Inc Company Overview
5.53 OncoGenesis Company Overview
5.54 Oxford Biodynamics Ltd Company Overview
5.55 Paragon Medical, Inc. Company Overview
5.56 PerkinElmer Inc Company Overview
5.57 Population Diagnostics Inc Company Overview
5.58 PreCyte, Inc. Company Overview
5.59 Premaitha Health Plc Company Overview
5.60 Prenetics Inc Company Overview
5.61 Qiagen NV Company Overview
5.62 Quest Diagnostics Inc Company Overview
5.63 R-Biopharm AG Company Overview
5.64 Sansure Biotech Inc Company Overview
5.65 Sapien Biosciences Company Overview
5.66 Sequenom Inc Company Overview
5.67 Sequoia Genetics Company Overview
5.68 Sheba Medical Center Company Overview
5.69 SkylineDx BV Company Overview
5.70 Spartan Bioscience Inc Company Overview
5.71 Strand Life Sciences Pvt Ltd Company Overview
5.72 The University of Utah Company Overview
5.73 Transgenomic Inc Company Overview
5.74 Transplant Genomics Inc. Company Overview
5.75 TrovaGene Inc Company Overview
5.76 Tufts Medical Center Company Overview
5.77 University Hospital of Cologne Company Overview
5.78 University of Colorado Company Overview
5.79 University of Texas Health Science Center at Houston Company Overview
5.80 VitaPath Genetics, Inc. Company Overview
5.81 Xiamen Zeesan Biotech Co.,Ltd Company Overview
6 Inborn Gene or Chromosome Alterations- Recent Developments
6.1 Dec 07, 2016: Illumina appoints senior vice president and CFO
6.2 Dec 07, 2016: Illumina Extends Management Team, Appoints Sam A. Samad as Senior Vice President and Chief Financial Officer
6.3 Dec 05, 2016: NxGen MDx announces the move of their Non-invasive Prenatal Test in-house
6.4 Dec 05, 2016: Good Start Genetics Enters into Marketing Agreement with Roche Diagnostics
6.5 Dec 02, 2016: GeneNews to Raise USD3 Million in Private Placement of 8% Debentures Due 2019
6.6 Dec 01, 2016: The Centers For Medicare And Medicaid Services Establishes 2017 Pricing For Aneuploidy And Microdeletion Testing
6.7 Nov 29, 2016: CombiMatrix’s Pre-Implantation Genetic Screening by Next Generation Sequencing Granted Conditional Approval from New York State Department of Health
6.8 Nov 29, 2016: SenzaGen awarded EU grant of € 2,4 million in heavy competition, to develop GARDair for industry use
6.9 Nov 21, 2016: Premaitha establishes first service laboratory customer in Asia
6.10 Nov 17, 2016: genedrive Announces CE-IVD Certification for Genedrive Human Genotyping Test
6.11 Nov 15, 2016: Interleukin Genetics Reports Third Quarter 2016 Financial Results
6.12 Nov 14, 2016: Prospective clinical follow-up study with over 2,200 patients confirms high test accuracy of PrenaTest for fetal trisomies
6.13 Nov 11, 2016: GeneNews Announces Q3-2016 Financial Results and Provides Corporate Update
6.14 Nov 10, 2016: Avellino Labs to Introduce Keratoconus Screening Test in early 2017
6.15 Nov 09, 2016: Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments
6.16 Nov 09, 2016: Natera Reports Third Quarter 2016 Financial Results
6.17 Nov 09, 2016: Daniel B. Polley, Ph.D., appointed Director of Lauer Tinnitus Research Center at Mass. Eye and Ear
6.18 Nov 03, 2016: GenMark Diagnostics Reports Q3 Financial Results
6.19 Nov 03, 2016: Fluidigm Announces Third Quarter Financial Results
6.20 Nov 02, 2016: CombiMatrix Reports Third Quarter 2016 Financial and Operating Results
6.21 Nov 02, 2016: QIAGEN Reports Results for Third Quarter and First Nine Months of 2016
6.22 Nov 02, 2016: Hologic Announces Financial Results for Fourth Quarter of Fiscal 2016
6.23 Nov 02, 2016: QIAGEN launches restructuring initiatives, revises outlook for 2016 earnings and provides initial net sales and adjusted earnings guidance for 2017
6.24 Nov 01, 2016: Illumina Reports Full Financial Results for Third Quarter of Fiscal Year 2016
6.25 Nov 01, 2016: Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results
6.26 Nov 01, 2016: Asuragen Launches QuantideX NGS RNA Lung Cancer Kit
6.27 Oct 31, 2016: NHS to adopt NIPT for high risk women
6.28 Oct 31, 2016: Luminex Reports Third Quarter 2016 Results; Raises Full Year Guidance
6.29 Oct 27, 2016: Thermo Fisher Scientific Reports Third Quarter 2016 Results
6.30 Oct 26, 2016: Laboratory Corporation of America Holdings Announces 2016 Third Quarter Results and Updates 2016 Guidance
6.31 Oct 25, 2016: Oxford BioDynamics presents results of study into epigenetic biomarkers for ALS at The Lancet Neurology Conference
6.32 Oct 24, 2016: German Court Issues Preliminary Injunction Against amedes Fetalis Test for Infringement of Non-Invasive Prenatal Screening Patent
6.33 Oct 24, 2016: ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016
6.34 Oct 24, 2016: Analysis of rare circulating fetal cells make possible a new type of noninvasive genetic prenatal testing
6.35 Oct 20, 2016: Quest Diagnostics Reports Third Quarter 2016 Financial Results
6.36 Oct 19, 2016: RainDance Technologies Showcases the Power and Precision of Its Picodroplet Platform at ASHG 2016 Annual Meeting
6.37 Oct 19, 2016: Lineagen Announces Presentation at Annual Meeting of the American Society of Human Genetics and Commercial Launch of a Proprietary Variant Index
6.38 Oct 19, 2016: Fluidigm Names S. Christopher Linthwaite as New Chief Executive Officer
6.39 Oct 17, 2016: Reprogenetics, Recombine, and Genesis Genetics Unite As Part of the CooperSurgical Family at ASRM 2016 Scientific Congress
6.40 Oct 14, 2016: IntegraGen Reports Revenues for First Half of 2016
6.41 Oct 13, 2016: Natera Announces Poster Presentation on Horizon carrier screen at the 2016 American Society for Reproductive Medicine (ASRM) Conference
6.42 Oct 13, 2016: Natera Announces Poster Presentation on Spectrum pre-implantation genetic test at the 2016 American Society for Reproductive Medicine (ASRM) Conference
6.43 Oct 12, 2016: Fluidigm Announces Preliminary Third Quarter 2016 Revenue
6.44 Oct 10, 2016: Illumina Announces Preliminary Revenue for Third Quarter of Fiscal Year 2016
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Glaucoma Surgery Devices Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2008-2022
Table 2: Glaucoma Surgery Devices Market, North America, Revenue ($m), Historic, USD Constant, 2008-2015
Table 3: Glaucoma Surgery Devices Market, North America, Revenue ($m), Forecast, USD Constant, 2015-2022
Table 4: Glaucoma Surgery Devices Market, North America, Volume (Units), 2008-2022
Table 5: Glaucoma Surgery Devices Market, North America, Volume (Units), Historic, 2008-2015
Table 6: Glaucoma Surgery Devices Market, North America, Volume (Units), Forecast, 2015-2022
Table 7: Glaucoma Surgery Devices Market, North America, Company Share by Revenue ($m), USD Constant, 2015
Table 8: Glaucoma Surgery Devices Market, Canada, Revenue ($m), USD Constant, Historic, 2008-2015
Table 9: Glaucoma Surgery Devices Market, Canada, Revenue ($m), USD Constant, Forecast, 2015-2022
Table 10: Glaucoma Surgery Devices Market, Canada, Volume (Units), Historic, 2008-2015
Table 11: Glaucoma Surgery Devices Market, Canada, Volume (Units), Forecast, 2015-2022
Table 12: Glaucoma Surgery Devices Market, Canada, Average Price ($), Historic, 2008-2015
Table 13: Glaucoma Surgery Devices Market, Canada, Average Price ($), Forecast, 2015-2022
Table 14: Glaucoma Surgery Devices Market, Canada, Distribution Share by Revenue ($m), USD Constant, 2014-2015
Table 15: Glaucoma Surgery Devices Market, Canada, Company Share by Revenue ($m), USD Constant, 2015
Table 16: Glaucoma Surgery Devices Market, Mexico, Revenue ($m), USD Constant, Historic, 2008-2015
Table 17: Glaucoma Surgery Devices Market, Mexico, Revenue ($m), USD Constant, Forecast, 2015-2022
Table 18: Glaucoma Surgery Devices Market, Mexico, Volume (Units), Historic, 2008-2015
Table 19: Glaucoma Surgery Devices Market, Mexico, Volume (Units), Forecast, 2015-2022
Table 20: Glaucoma Surgery Devices Market, Mexico, Average Price ($), Historic, 2008-2015
Table 21: Glaucoma Surgery Devices Market, Mexico, Average Price ($), Forecast, 2015-2022
Table 22: Glaucoma Surgery Devices Market, Mexico, Distribution Share by Revenue ($m), USD Constant, 2014-2015
Table 23: Glaucoma Surgery Devices Market, Mexico, Company Share by Revenue ($m), USD Constant, 2015
Table 24: Glaucoma Surgery Devices Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015
Table 25: Glaucoma Surgery Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022
Table 26: Glaucoma Surgery Devices Market, United States, Volume (Units), Historic, 2008-2015
Table 27: Glaucoma Surgery Devices Market, United States, Volume (Units), Forecast, 2015-2022
Table 28: Glaucoma Surgery Devices Market, United States, Average Price ($), Historic, 2008-2015
Table 29: Glaucoma Surgery Devices Market, United States, Average Price ($), Forecast, 2015-2022
Table 30: Glaucoma Surgery Devices Market, United States, Distribution Share by Revenue ($m), USD Constant, 2014-2015
Table 31: Glaucoma Surgery Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2015
Table 32: Glaucoma Surgery Devices Market Pipeline Products
1.2 List of Figures
Figure 1: Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
Figure 2: Inborn Gene or Chromosome Alterations - Pipeline Products by Territory
Figure 3: Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
Figure 4: Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date
Figure 5: Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report